The present invention relates to pyrrolopyridine-3-yl group containing β 3 adrenergic receptor agonists or pharmaceutical salts thereof.
1. A compound of the formula:
wherein:
m is 2;
n is 0 or 1;
A 1 , A 2 and A 3 are carbon;
Het is at the ortho position relative to X and is thien-2-yl optionally substituted with CN or CH 3 ;
R 1 , R 2 and R 3 are H;
R 4 and R 5 are independently H or methyl at each occurrence;
R 6 is independently at each occurrence methyl;
R 7 is at the 6- or 7-position of the 6,5 ring system to which it is attached and is selected from H, O(CH 2 ) p R 12 or thienyl;
X is OCH 2 ;
p is 0 or 1; and
R 12 is CONH 2 , phenyl or pyridyl substituted once with CONH 2 ; or a pharmaceutical salt thereof.
2. A compound which is:
or a pharmaceutical salt thereof.
3. The compound of claim 1 which is the hydrochloride salt.
4. A pharmaceutical formulation comprising a compound of claim 1 and a pharmaceutical carrier.
5. A method of treating Type 2 Diabetes comprising administering to a patient in need thereof a compound of claim 1 .
6. A method of treating obesity comprising administering to a patient in need thereof an effective amount of a compound of claim 1 .